PharmiWeb.com - Global Pharma News & Resources
16-Nov-2021

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH PROVISIONAL INTERIM RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cassiopea S.p.A. / Key word(s): Takeover

16-Nov-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland and Lainate, Italy - 16 November 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") announced today that during the offer period of the public exchange offer in Switzerland for Cosmo to acquire all of the publicly held registered shares of Cassiopea, which ended on 15 November 2021, the preliminary results show that shareholders have tendered 4,394,985 shares of Cassiopea, amounting to approximately 76.5% of the publicly held Cassiopea shares covered by the offer, which together with the Cassiopea shares already held by Cosmo equates to approximately 87.4% of the Cassiopea shares currently issued.

Alessandro Della Cha, CEO of Cosmo, said: "We are delighted that the offer acceptance has so significantly exceeded the minimum threshold of Cosmo owning 50% of Cassiopea. Following settlement, we will move expeditiously with the full integration of the two companies for the benefit of all shareholders."  

Mauro Ajani, Chairman of Cosmo, said: "I am very happy about this great outcome. Combining the companies at this point in time has been the right move for all." 

Cosmo will address whether the other relevant offer conditions have been satisfied or waived in the definitive notice of the interim results per the conditions of section B.8. of the offer prospectus dated 4 October 2021. The definitive notice of the interim results is expected to be published on 18 November 2021.

Following settlement of the offer, Cosmo intends to delist the Cassiopea shares from the SIX Swiss Exchange and, as a result, Cassiopea is expected to become a non-listed majority owned subsidiary of Cosmo.

A shareholders' meeting will be convened to appoint new members to the Board of Directors of Cassiopea following the resignations of Ms. Diana Harbort and Messrs Jan De Vries and Oyvind Bjordal, effective from the date of such shareholders' meeting which is expected to take place before the end of January, 2022.

Ms. Diana Harbort, Cassiopea's Chief Executive Officer, as previously communicated, will transition from her role following settlement of the offer and be appointed as President of Cosmo's newly established dermatology division, which will include Cassiopea's current business activities.

Further information is available on https://www.cosmopharma.com/news-and-media/news-releases/2021/211116 and on https://www.cassiopea.com/web-filter/

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo(TM) to Red Hill Biopharma and is the licensee of BYFAVO(TM) (Remimazolam) for the US for procedural sedation, which it has sub-licensed to Acacia. For additional information on Cosmo and its products please visit the Company's website: www.cassiopea.com

About Cassiopea
Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products directly or with partners. For further information on Cassiopea, please visit  www.cassiopea.com.

Contact  
Niall Donnelly, CFO & Head of Investor Relations Diana Harbort, CEO & Head of Investor Relations
Cosmo Pharmaceuticals N.V. Cassiopea S.p.A.
Tel: +353 1 817 03 70 Tel: +39 02 868 911 24,
ndonnelly@cosmopharma.com dharbort@cassiopea.com


End of ad hoc announcement
Language: English
Company: Cassiopea S.p.A.
Via Cristoforo Colombo 1
20045 Lainate
Switzerland
E-mail: info@cassiopea.com
Internet: https://www.cassiopea.com/
ISIN: IT0005108359
Listed: SIX Swiss Exchange
EQS News ID: 1249263

 
End of Announcement EQS Group News Service

Editor Details

Last Updated: 17-Nov-2021